| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 271 | 2026 | 2121 | 41.280 |
Why?
|
| Atherosclerosis | 132 | 2026 | 948 | 28.450 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 132 | 2026 | 744 | 25.970 |
Why?
|
| Cardiology | 58 | 2026 | 514 | 16.160 |
Why?
|
| Coronary Artery Disease | 79 | 2026 | 887 | 14.510 |
Why?
|
| Cholesterol, LDL | 84 | 2026 | 604 | 11.160 |
Why?
|
| Anticholesteremic Agents | 39 | 2026 | 239 | 11.120 |
Why?
|
| Dyslipidemias | 41 | 2026 | 256 | 10.560 |
Why?
|
| American Heart Association | 66 | 2026 | 343 | 8.690 |
Why?
|
| United States | 278 | 2026 | 12072 | 7.950 |
Why?
|
| Diabetes Mellitus | 50 | 2025 | 889 | 7.810 |
Why?
|
| Risk Assessment | 129 | 2026 | 3711 | 7.480 |
Why?
|
| Primary Prevention | 45 | 2026 | 183 | 7.370 |
Why?
|
| Stroke | 55 | 2024 | 1061 | 7.310 |
Why?
|
| Risk Factors | 258 | 2026 | 11074 | 7.300 |
Why?
|
| Hypercholesterolemia | 28 | 2025 | 230 | 6.990 |
Why?
|
| Cholesterol | 39 | 2023 | 539 | 6.530 |
Why?
|
| Humans | 688 | 2026 | 131163 | 6.190 |
Why?
|
| Practice Guidelines as Topic | 51 | 2026 | 1295 | 5.640 |
Why?
|
| Secondary Prevention | 28 | 2026 | 217 | 5.340 |
Why?
|
| Hypolipidemic Agents | 22 | 2026 | 202 | 5.270 |
Why?
|
| Myocardial Infarction | 42 | 2026 | 999 | 5.240 |
Why?
|
| Hypertension | 39 | 2024 | 1356 | 5.090 |
Why?
|
| Middle Aged | 289 | 2026 | 28601 | 4.940 |
Why?
|
| Practice Patterns, Physicians' | 28 | 2023 | 789 | 4.910 |
Why?
|
| Coronary Disease | 32 | 2024 | 624 | 4.830 |
Why?
|
| Heart Failure | 52 | 2024 | 2332 | 4.780 |
Why?
|
| Aged | 237 | 2026 | 21025 | 4.720 |
Why?
|
| Registries | 52 | 2024 | 1634 | 4.640 |
Why?
|
| Lipoprotein(a) | 22 | 2025 | 142 | 4.600 |
Why?
|
| Percutaneous Coronary Intervention | 25 | 2026 | 299 | 4.320 |
Why?
|
| Vascular Calcification | 14 | 2025 | 70 | 4.300 |
Why?
|
| Proprotein Convertase 9 | 25 | 2024 | 108 | 4.220 |
Why?
|
| Healthcare Disparities | 24 | 2026 | 523 | 4.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 27 | 2026 | 1459 | 4.170 |
Why?
|
| Coronary Artery Bypass | 25 | 2026 | 515 | 4.040 |
Why?
|
| Male | 345 | 2026 | 64957 | 4.030 |
Why?
|
| Guideline Adherence | 32 | 2020 | 387 | 3.980 |
Why?
|
| Myocardial Ischemia | 13 | 2025 | 307 | 3.940 |
Why?
|
| Lipids | 26 | 2025 | 569 | 3.900 |
Why?
|
| Female | 344 | 2026 | 70963 | 3.780 |
Why?
|
| Platelet Aggregation Inhibitors | 17 | 2021 | 267 | 3.610 |
Why?
|
| Medication Adherence | 17 | 2022 | 338 | 3.570 |
Why?
|
| Metabolic Syndrome | 13 | 2026 | 369 | 3.400 |
Why?
|
| Behavioral Risk Factor Surveillance System | 17 | 2023 | 51 | 3.280 |
Why?
|
| Adult | 172 | 2026 | 31282 | 3.210 |
Why?
|
| United States Department of Veterans Affairs | 19 | 2024 | 729 | 3.190 |
Why?
|
| Veterans | 21 | 2024 | 1763 | 3.040 |
Why?
|
| Eicosapentaenoic Acid | 9 | 2023 | 82 | 3.040 |
Why?
|
| Acute Coronary Syndrome | 15 | 2024 | 235 | 2.890 |
Why?
|
| Prevalence | 49 | 2025 | 2701 | 2.860 |
Why?
|
| Hyperlipidemias | 13 | 2023 | 185 | 2.850 |
Why?
|
| Heart Diseases | 21 | 2025 | 499 | 2.800 |
Why?
|
| Renal Insufficiency, Chronic | 21 | 2023 | 853 | 2.720 |
Why?
|
| Hypertriglyceridemia | 8 | 2025 | 117 | 2.680 |
Why?
|
| Cholesterol, HDL | 26 | 2025 | 383 | 2.630 |
Why?
|
| Cardio-Renal Syndrome | 6 | 2026 | 24 | 2.620 |
Why?
|
| Aspirin | 11 | 2023 | 211 | 2.580 |
Why?
|
| Biomarkers | 71 | 2026 | 3385 | 2.570 |
Why?
|
| Plaque, Atherosclerotic | 13 | 2024 | 150 | 2.540 |
Why?
|
| Peripheral Arterial Disease | 13 | 2026 | 326 | 2.520 |
Why?
|
| Atrial Fibrillation | 17 | 2023 | 738 | 2.510 |
Why?
|
| Ezetimibe | 15 | 2022 | 93 | 2.480 |
Why?
|
| Cigarette Smoking | 5 | 2021 | 92 | 2.440 |
Why?
|
| Health Expenditures | 15 | 2020 | 136 | 2.440 |
Why?
|
| Electronic Nicotine Delivery Systems | 4 | 2020 | 60 | 2.390 |
Why?
|
| Blood Pressure | 24 | 2024 | 1345 | 2.390 |
Why?
|
| Drug Monitoring | 9 | 2021 | 292 | 2.330 |
Why?
|
| Drug Costs | 5 | 2019 | 66 | 2.330 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2023 | 1267 | 2.300 |
Why?
|
| Hyperlipoproteinemia Type II | 11 | 2023 | 119 | 2.250 |
Why?
|
| Social Determinants of Health | 11 | 2026 | 165 | 2.210 |
Why?
|
| Nurse Practitioners | 5 | 2021 | 50 | 2.190 |
Why?
|
| Smoking Cessation | 9 | 2024 | 191 | 2.150 |
Why?
|
| ST Elevation Myocardial Infarction | 11 | 2022 | 117 | 2.130 |
Why?
|
| Physician Assistants | 5 | 2021 | 81 | 2.130 |
Why?
|
| Cross-Sectional Studies | 40 | 2025 | 3829 | 2.120 |
Why?
|
| Drug Prescriptions | 12 | 2020 | 237 | 2.060 |
Why?
|
| Triglycerides | 21 | 2026 | 602 | 2.060 |
Why?
|
| Risk Reduction Behavior | 13 | 2022 | 143 | 2.060 |
Why?
|
| Carotid Artery Diseases | 10 | 2020 | 130 | 2.050 |
Why?
|
| Veterans Health | 9 | 2021 | 170 | 2.000 |
Why?
|
| Time Factors | 58 | 2026 | 6196 | 1.970 |
Why?
|
| Telemedicine | 11 | 2026 | 526 | 1.920 |
Why?
|
| Treatment Outcome | 83 | 2026 | 12936 | 1.910 |
Why?
|
| Lipoproteins | 13 | 2026 | 183 | 1.910 |
Why?
|
| Aged, 80 and over | 62 | 2025 | 6797 | 1.880 |
Why?
|
| C-Reactive Protein | 15 | 2025 | 450 | 1.850 |
Why?
|
| Health Status Disparities | 8 | 2026 | 282 | 1.850 |
Why?
|
| Sex Factors | 24 | 2025 | 1356 | 1.840 |
Why?
|
| Quality Improvement | 8 | 2020 | 722 | 1.840 |
Why?
|
| Calcium | 14 | 2024 | 1010 | 1.800 |
Why?
|
| Coronary Vessels | 13 | 2023 | 521 | 1.790 |
Why?
|
| Hospital Mortality | 22 | 2024 | 1064 | 1.780 |
Why?
|
| Ambulatory Care | 11 | 2022 | 401 | 1.770 |
Why?
|
| Cardiovascular Agents | 5 | 2024 | 88 | 1.730 |
Why?
|
| Football | 5 | 2014 | 39 | 1.680 |
Why?
|
| Aortic Valve Stenosis | 9 | 2023 | 350 | 1.650 |
Why?
|
| Clinical Decision-Making | 11 | 2026 | 314 | 1.630 |
Why?
|
| Brain Ischemia | 5 | 2023 | 266 | 1.630 |
Why?
|
| Cardiovascular System | 3 | 2024 | 97 | 1.620 |
Why?
|
| Age Factors | 31 | 2026 | 2825 | 1.550 |
Why?
|
| Cause of Death | 13 | 2026 | 506 | 1.540 |
Why?
|
| Smoking | 15 | 2024 | 932 | 1.520 |
Why?
|
| Women's Health | 3 | 2020 | 134 | 1.490 |
Why?
|
| Tobacco, Smokeless | 3 | 2021 | 10 | 1.470 |
Why?
|
| Antihypertensive Agents | 14 | 2024 | 414 | 1.470 |
Why?
|
| Primary Health Care | 10 | 2021 | 775 | 1.460 |
Why?
|
| Young Adult | 47 | 2026 | 10103 | 1.430 |
Why?
|
| Health Care Costs | 11 | 2026 | 407 | 1.410 |
Why?
|
| Delivery of Health Care | 12 | 2022 | 689 | 1.410 |
Why?
|
| Retrospective Studies | 71 | 2026 | 17753 | 1.400 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2019 | 38 | 1.360 |
Why?
|
| Incidence | 43 | 2025 | 3360 | 1.360 |
Why?
|
| Comorbidity | 26 | 2023 | 1595 | 1.350 |
Why?
|
| Mortality | 11 | 2025 | 264 | 1.330 |
Why?
|
| Obesity | 21 | 2026 | 2426 | 1.330 |
Why?
|
| Retirement | 4 | 2014 | 18 | 1.310 |
Why?
|
| Preventive Medicine | 3 | 2019 | 18 | 1.310 |
Why?
|
| Eligibility Determination | 6 | 2019 | 38 | 1.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 11 | 2026 | 919 | 1.290 |
Why?
|
| Odds Ratio | 22 | 2022 | 1211 | 1.290 |
Why?
|
| Vaping | 2 | 2021 | 31 | 1.270 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 981 | 1.270 |
Why?
|
| Life Style | 8 | 2026 | 456 | 1.250 |
Why?
|
| Income | 11 | 2024 | 138 | 1.240 |
Why?
|
| Nutrition Surveys | 12 | 2026 | 338 | 1.240 |
Why?
|
| Prospective Studies | 44 | 2025 | 6459 | 1.240 |
Why?
|
| Health Behavior | 7 | 2022 | 387 | 1.240 |
Why?
|
| Global Health | 15 | 2026 | 626 | 1.240 |
Why?
|
| Surveys and Questionnaires | 17 | 2023 | 4066 | 1.210 |
Why?
|
| Dicarboxylic Acids | 4 | 2023 | 37 | 1.210 |
Why?
|
| Health Personnel | 5 | 2026 | 541 | 1.210 |
Why?
|
| Physicians, Primary Care | 3 | 2021 | 100 | 1.210 |
Why?
|
| Health Services Accessibility | 9 | 2022 | 712 | 1.190 |
Why?
|
| Logistic Models | 21 | 2025 | 1797 | 1.170 |
Why?
|
| Societies, Medical | 7 | 2025 | 798 | 1.170 |
Why?
|
| Fish Oils | 2 | 2021 | 82 | 1.160 |
Why?
|
| Prediabetic State | 4 | 2024 | 68 | 1.160 |
Why?
|
| Hospitalization | 23 | 2025 | 1950 | 1.140 |
Why?
|
| Hypoglycemic Agents | 10 | 2025 | 480 | 1.130 |
Why?
|
| Follow-Up Studies | 32 | 2024 | 5196 | 1.110 |
Why?
|
| Pakistan | 12 | 2026 | 99 | 1.080 |
Why?
|
| Inpatients | 10 | 2023 | 562 | 1.070 |
Why?
|
| Patient Selection | 6 | 2019 | 729 | 1.060 |
Why?
|
| Evidence-Based Medicine | 10 | 2020 | 645 | 1.050 |
Why?
|
| Pandemics | 9 | 2023 | 1118 | 1.050 |
Why?
|
| Internet | 3 | 2020 | 420 | 1.050 |
Why?
|
| Stroke Volume | 8 | 2024 | 541 | 1.040 |
Why?
|
| Fatty Acids | 4 | 2023 | 377 | 1.030 |
Why?
|
| Attitude of Health Personnel | 4 | 2020 | 707 | 1.030 |
Why?
|
| Health Surveys | 8 | 2024 | 261 | 1.030 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 339 | 1.020 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 351 | 1.020 |
Why?
|
| Apolipoproteins B | 7 | 2024 | 142 | 1.000 |
Why?
|
| Quality Indicators, Health Care | 8 | 2020 | 240 | 1.000 |
Why?
|
| Reminder Systems | 2 | 2018 | 62 | 1.000 |
Why?
|
| Clinical Trials as Topic | 10 | 2024 | 1129 | 0.980 |
Why?
|
| Anticoagulants | 8 | 2021 | 605 | 0.980 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2023 | 425 | 0.980 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 6 | 2019 | 91 | 0.970 |
Why?
|
| Databases, Factual | 15 | 2026 | 1240 | 0.960 |
Why?
|
| Fibric Acids | 2 | 2023 | 7 | 0.950 |
Why?
|
| Congresses as Topic | 6 | 2025 | 184 | 0.940 |
Why?
|
| Quality of Health Care | 5 | 2019 | 413 | 0.930 |
Why?
|
| Body Mass Index | 10 | 2021 | 1717 | 0.930 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 496 | 0.930 |
Why?
|
| Inflammation | 7 | 2025 | 1489 | 0.920 |
Why?
|
| Prognosis | 31 | 2026 | 4886 | 0.910 |
Why?
|
| Noncommunicable Diseases | 3 | 2023 | 22 | 0.910 |
Why?
|
| Fibrinolytic Agents | 4 | 2020 | 182 | 0.910 |
Why?
|
| Exercise | 10 | 2023 | 892 | 0.900 |
Why?
|
| Postoperative Complications | 11 | 2021 | 3147 | 0.900 |
Why?
|
| Communication | 5 | 2021 | 543 | 0.900 |
Why?
|
| Diabetes Complications | 6 | 2021 | 197 | 0.900 |
Why?
|
| Adolescent | 38 | 2026 | 20987 | 0.890 |
Why?
|
| Europe | 6 | 2025 | 365 | 0.880 |
Why?
|
| Nutrition Policy | 2 | 2026 | 96 | 0.880 |
Why?
|
| Sex Characteristics | 3 | 2020 | 323 | 0.880 |
Why?
|
| Severity of Illness Index | 15 | 2024 | 3061 | 0.870 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2020 | 2833 | 0.870 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2021 | 20 | 0.870 |
Why?
|
| Preventive Health Services | 3 | 2020 | 59 | 0.860 |
Why?
|
| Tobacco Use | 3 | 2021 | 29 | 0.860 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2023 | 214 | 0.840 |
Why?
|
| Blood Glucose | 8 | 2022 | 1117 | 0.830 |
Why?
|
| Age of Onset | 4 | 2025 | 592 | 0.830 |
Why?
|
| Thiophenes | 2 | 2014 | 69 | 0.820 |
Why?
|
| Lipid Regulating Agents | 2 | 2020 | 6 | 0.810 |
Why?
|
| Social Media | 3 | 2022 | 120 | 0.810 |
Why?
|
| Transcatheter Aortic Valve Replacement | 6 | 2023 | 228 | 0.810 |
Why?
|
| Prescription Drugs | 2 | 2014 | 54 | 0.800 |
Why?
|
| Periodontal Diseases | 3 | 2023 | 31 | 0.800 |
Why?
|
| Neoplasms | 6 | 2023 | 3016 | 0.800 |
Why?
|
| Rivaroxaban | 2 | 2021 | 49 | 0.790 |
Why?
|
| Predictive Value of Tests | 18 | 2023 | 2304 | 0.790 |
Why?
|
| Calcinosis | 5 | 2022 | 180 | 0.790 |
Why?
|
| Ventricular Function, Left | 5 | 2022 | 549 | 0.790 |
Why?
|
| Survival Rate | 17 | 2024 | 2114 | 0.780 |
Why?
|
| Tobacco Products | 2 | 2021 | 60 | 0.780 |
Why?
|
| Cerebrovascular Disorders | 4 | 2024 | 111 | 0.780 |
Why?
|
| Research Design | 3 | 2026 | 716 | 0.780 |
Why?
|
| Cohort Studies | 25 | 2024 | 5063 | 0.770 |
Why?
|
| Inflammation Mediators | 2 | 2025 | 226 | 0.770 |
Why?
|
| Multivariate Analysis | 11 | 2021 | 1378 | 0.760 |
Why?
|
| Influenza Vaccines | 3 | 2022 | 507 | 0.760 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2023 | 205 | 0.750 |
Why?
|
| Metabolic Diseases | 3 | 2025 | 143 | 0.740 |
Why?
|
| Medication Therapy Management | 6 | 2018 | 22 | 0.740 |
Why?
|
| Population Surveillance | 2 | 2022 | 396 | 0.740 |
Why?
|
| Piperazines | 2 | 2014 | 265 | 0.740 |
Why?
|
| Policy Making | 2 | 2019 | 63 | 0.740 |
Why?
|
| Physicians | 3 | 2023 | 635 | 0.730 |
Why?
|
| Publishing | 1 | 2024 | 105 | 0.730 |
Why?
|
| Shock, Cardiogenic | 9 | 2023 | 176 | 0.730 |
Why?
|
| Coronary Angiography | 11 | 2025 | 450 | 0.730 |
Why?
|
| Patient Care Planning | 2 | 2021 | 124 | 0.730 |
Why?
|
| Cost of Illness | 6 | 2025 | 297 | 0.720 |
Why?
|
| Dietary Supplements | 4 | 2021 | 448 | 0.720 |
Why?
|
| Natriuretic Peptide, Brain | 10 | 2023 | 325 | 0.720 |
Why?
|
| India | 8 | 2020 | 234 | 0.710 |
Why?
|
| Simvastatin | 4 | 2017 | 76 | 0.710 |
Why?
|
| Foreign-Body Migration | 2 | 2015 | 65 | 0.700 |
Why?
|
| Medicaid | 2 | 2021 | 268 | 0.700 |
Why?
|
| Cinnamomum zeylanicum | 1 | 2021 | 2 | 0.700 |
Why?
|
| Global Burden of Disease | 5 | 2026 | 37 | 0.690 |
Why?
|
| Myocardial Perfusion Imaging | 3 | 2019 | 60 | 0.690 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 29 | 0.690 |
Why?
|
| Plant Preparations | 1 | 2021 | 15 | 0.690 |
Why?
|
| Acute Kidney Injury | 5 | 2022 | 705 | 0.690 |
Why?
|
| Physician-Patient Relations | 3 | 2021 | 441 | 0.690 |
Why?
|
| Cardiotonic Agents | 2 | 2022 | 138 | 0.680 |
Why?
|
| Kidney Diseases | 1 | 2026 | 477 | 0.680 |
Why?
|
| Unsafe Sex | 1 | 2021 | 23 | 0.680 |
Why?
|
| Docosahexaenoic Acids | 2 | 2019 | 67 | 0.680 |
Why?
|
| Troponin T | 9 | 2023 | 259 | 0.680 |
Why?
|
| Marijuana Use | 1 | 2021 | 14 | 0.670 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 42 | 0.670 |
Why?
|
| Diabetic Nephropathies | 2 | 2021 | 115 | 0.670 |
Why?
|
| Diet Therapy | 1 | 2021 | 40 | 0.670 |
Why?
|
| Phytotherapy | 1 | 2021 | 48 | 0.670 |
Why?
|
| Military Medicine | 1 | 2021 | 52 | 0.670 |
Why?
|
| Preoperative Care | 4 | 2012 | 358 | 0.660 |
Why?
|
| Office Visits | 2 | 2019 | 80 | 0.660 |
Why?
|
| Outpatients | 3 | 2018 | 262 | 0.650 |
Why?
|
| Socioeconomic Factors | 12 | 2025 | 915 | 0.650 |
Why?
|
| Protective Factors | 8 | 2021 | 91 | 0.650 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 161 | 0.650 |
Why?
|
| Counseling | 2 | 2019 | 238 | 0.650 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2021 | 80 | 0.650 |
Why?
|
| Goals | 2 | 2011 | 126 | 0.650 |
Why?
|
| Budgets | 1 | 2020 | 15 | 0.640 |
Why?
|
| Government Regulation | 1 | 2020 | 44 | 0.640 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2020 | 3 | 0.640 |
Why?
|
| Lipoproteins, LDL | 3 | 2021 | 119 | 0.640 |
Why?
|
| Renal Insufficiency | 4 | 2011 | 259 | 0.640 |
Why?
|
| Rheumatic Fever | 1 | 2020 | 20 | 0.630 |
Why?
|
| Carotid Arteries | 5 | 2022 | 124 | 0.630 |
Why?
|
| Denervation | 1 | 2020 | 24 | 0.630 |
Why?
|
| Research Report | 9 | 2019 | 73 | 0.620 |
Why?
|
| Kidney | 6 | 2023 | 1282 | 0.620 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2026 | 570 | 0.620 |
Why?
|
| Biological Specimen Banks | 2 | 2022 | 72 | 0.620 |
Why?
|
| Cardiomyopathies | 4 | 2016 | 514 | 0.610 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 60 | 0.610 |
Why?
|
| Interleukins | 1 | 2020 | 122 | 0.610 |
Why?
|
| Exercise Test | 3 | 2020 | 239 | 0.610 |
Why?
|
| Consensus | 7 | 2022 | 512 | 0.610 |
Why?
|
| Health Literacy | 3 | 2019 | 77 | 0.610 |
Why?
|
| Community Health Workers | 4 | 2026 | 87 | 0.610 |
Why?
|
| Morbidity | 8 | 2020 | 256 | 0.600 |
Why?
|
| Healthy Lifestyle | 5 | 2019 | 33 | 0.590 |
Why?
|
| Educational Status | 7 | 2023 | 279 | 0.590 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 139 | 0.590 |
Why?
|
| Television | 1 | 2019 | 70 | 0.580 |
Why?
|
| Echocardiography, Stress | 1 | 2019 | 19 | 0.580 |
Why?
|
| Transients and Migrants | 1 | 2019 | 30 | 0.580 |
Why?
|
| Diuretics | 3 | 2022 | 159 | 0.570 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2019 | 109 | 0.570 |
Why?
|
| Texas | 15 | 2026 | 3686 | 0.570 |
Why?
|
| Emigration and Immigration | 1 | 2019 | 80 | 0.570 |
Why?
|
| Alcoholism | 1 | 2021 | 244 | 0.570 |
Why?
|
| Patient Care Team | 3 | 2025 | 562 | 0.570 |
Why?
|
| Patient Preference | 1 | 2020 | 151 | 0.570 |
Why?
|
| Asia | 7 | 2024 | 124 | 0.560 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 2019 | 216 | 0.560 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2025 | 239 | 0.560 |
Why?
|
| Cost-Benefit Analysis | 7 | 2020 | 555 | 0.560 |
Why?
|
| Thinness | 1 | 2019 | 71 | 0.560 |
Why?
|
| Health Information Systems | 1 | 2018 | 34 | 0.550 |
Why?
|
| Biological Products | 1 | 2020 | 145 | 0.550 |
Why?
|
| Aortic Valve | 8 | 2023 | 455 | 0.550 |
Why?
|
| Patient Education as Topic | 3 | 2026 | 464 | 0.540 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 376 | 0.540 |
Why?
|
| Survivors | 2 | 2023 | 344 | 0.520 |
Why?
|
| Coronary Stenosis | 3 | 2021 | 78 | 0.520 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 132 | 0.510 |
Why?
|
| Patient Protection and Affordable Care Act | 4 | 2022 | 70 | 0.510 |
Why?
|
| Asymptomatic Diseases | 6 | 2024 | 77 | 0.510 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 229 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 512 | 0.510 |
Why?
|
| Health Services | 2 | 2016 | 69 | 0.500 |
Why?
|
| Pyrimidines | 1 | 2020 | 446 | 0.500 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 327 | 0.490 |
Why?
|
| Peptide Fragments | 8 | 2023 | 687 | 0.490 |
Why?
|
| Apolipoprotein C-III | 4 | 2025 | 46 | 0.490 |
Why?
|
| Drug Therapy, Combination | 11 | 2021 | 1173 | 0.480 |
Why?
|
| Propensity Score | 4 | 2012 | 271 | 0.480 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2013 | 39 | 0.480 |
Why?
|
| Proportional Hazards Models | 16 | 2025 | 1410 | 0.480 |
Why?
|
| Warfarin | 4 | 2021 | 121 | 0.470 |
Why?
|
| Drug Utilization | 5 | 2020 | 164 | 0.470 |
Why?
|
| Amino Acids | 2 | 2018 | 566 | 0.470 |
Why?
|
| Cardiorespiratory Fitness | 3 | 2020 | 12 | 0.470 |
Why?
|
| Inservice Training | 1 | 2016 | 56 | 0.460 |
Why?
|
| Colchicine | 4 | 2021 | 40 | 0.460 |
Why?
|
| Carotid Stenosis | 2 | 2021 | 106 | 0.450 |
Why?
|
| Advisory Committees | 5 | 2019 | 150 | 0.440 |
Why?
|
| Angiotensin Receptor Antagonists | 6 | 2024 | 133 | 0.440 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 4 | 2021 | 43 | 0.440 |
Why?
|
| Lipoproteins, HDL | 3 | 2024 | 97 | 0.440 |
Why?
|
| Niacin | 4 | 2013 | 59 | 0.440 |
Why?
|
| Health Status | 8 | 2024 | 378 | 0.430 |
Why?
|
| Attitude to Health | 4 | 2020 | 247 | 0.430 |
Why?
|
| Carotid Artery, Internal | 2 | 2015 | 55 | 0.430 |
Why?
|
| Heart Ventricles | 2 | 2021 | 749 | 0.430 |
Why?
|
| Heart Injuries | 1 | 2015 | 48 | 0.430 |
Why?
|
| Medical Informatics | 1 | 2016 | 107 | 0.430 |
Why?
|
| Angina Pectoris | 1 | 2015 | 56 | 0.430 |
Why?
|
| Carotid Intima-Media Thickness | 8 | 2022 | 77 | 0.430 |
Why?
|
| Poverty | 4 | 2025 | 462 | 0.420 |
Why?
|
| Premature Birth | 1 | 2019 | 428 | 0.420 |
Why?
|
| Geriatrics | 2 | 2025 | 74 | 0.420 |
Why?
|
| Vascular Diseases | 1 | 2016 | 146 | 0.420 |
Why?
|
| Electrocardiography | 7 | 2017 | 970 | 0.420 |
Why?
|
| Waist Circumference | 1 | 2014 | 94 | 0.420 |
Why?
|
| Occupations | 1 | 2014 | 17 | 0.410 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 78 | 0.410 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 231 | 0.410 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2021 | 1168 | 0.410 |
Why?
|
| Medicare | 5 | 2022 | 442 | 0.410 |
Why?
|
| Wounds, Penetrating | 1 | 2015 | 140 | 0.410 |
Why?
|
| Bayes Theorem | 3 | 2024 | 311 | 0.410 |
Why?
|
| Amyloidosis | 1 | 2015 | 70 | 0.410 |
Why?
|
| Health Care Surveys | 7 | 2022 | 276 | 0.400 |
Why?
|
| Defibrillators, Implantable | 2 | 2024 | 215 | 0.400 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 109 | 0.400 |
Why?
|
| Athletes | 1 | 2014 | 77 | 0.400 |
Why?
|
| Carotid Artery, Common | 2 | 2011 | 59 | 0.400 |
Why?
|
| Echocardiography | 7 | 2023 | 1125 | 0.390 |
Why?
|
| Electronic Health Records | 2 | 2018 | 844 | 0.390 |
Why?
|
| Thrombolytic Therapy | 3 | 2020 | 191 | 0.390 |
Why?
|
| Cell Phone | 3 | 2019 | 33 | 0.390 |
Why?
|
| Dementia | 3 | 2023 | 436 | 0.390 |
Why?
|
| Saphenous Vein | 2 | 2012 | 49 | 0.380 |
Why?
|
| Betacoronavirus | 3 | 2020 | 275 | 0.380 |
Why?
|
| Neck | 1 | 2014 | 140 | 0.380 |
Why?
|
| DNA | 2 | 2020 | 1399 | 0.380 |
Why?
|
| Residence Characteristics | 4 | 2025 | 295 | 0.380 |
Why?
|
| Vascular Stiffness | 4 | 2021 | 76 | 0.380 |
Why?
|
| Interleukin-6 | 4 | 2023 | 412 | 0.370 |
Why?
|
| Fenofibrate | 4 | 2014 | 59 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 5 | 2023 | 934 | 0.370 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 2 | 2017 | 29 | 0.360 |
Why?
|
| Patient-Centered Care | 3 | 2021 | 236 | 0.360 |
Why?
|
| Chest Pain | 3 | 2025 | 133 | 0.360 |
Why?
|
| Hearing Loss | 2 | 2025 | 204 | 0.360 |
Why?
|
| Longitudinal Studies | 7 | 2026 | 1490 | 0.360 |
Why?
|
| Hemorrhage | 6 | 2023 | 487 | 0.350 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 554 | 0.350 |
Why?
|
| Heart Valves | 2 | 2010 | 52 | 0.350 |
Why?
|
| Middle East | 2 | 2023 | 36 | 0.350 |
Why?
|
| Oxazolidinones | 1 | 2011 | 32 | 0.350 |
Why?
|
| Cardiologists | 2 | 2023 | 26 | 0.350 |
Why?
|
| Heart Valve Diseases | 3 | 2022 | 162 | 0.340 |
Why?
|
| Needs Assessment | 3 | 2023 | 173 | 0.340 |
Why?
|
| United Kingdom | 5 | 2025 | 267 | 0.340 |
Why?
|
| Awareness | 3 | 2020 | 78 | 0.340 |
Why?
|
| Insurance, Health | 3 | 2021 | 146 | 0.330 |
Why?
|
| Sex Distribution | 6 | 2026 | 318 | 0.330 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2022 | 3763 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 53 | 0.330 |
Why?
|
| Frailty | 2 | 2024 | 140 | 0.330 |
Why?
|
| Pilot Projects | 6 | 2022 | 1445 | 0.330 |
Why?
|
| Mental Health | 3 | 2026 | 378 | 0.330 |
Why?
|
| RNA, Small Interfering | 2 | 2024 | 664 | 0.320 |
Why?
|
| Medical History Taking | 2 | 2021 | 107 | 0.320 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2023 | 129 | 0.320 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 53 | 0.320 |
Why?
|
| Geography | 2 | 2020 | 114 | 0.320 |
Why?
|
| Urban Population | 2 | 2025 | 287 | 0.320 |
Why?
|
| Data Collection | 3 | 2023 | 370 | 0.310 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2016 | 161 | 0.310 |
Why?
|
| Financing, Personal | 2 | 2020 | 14 | 0.310 |
Why?
|
| Glomerular Filtration Rate | 5 | 2021 | 566 | 0.310 |
Why?
|
| Drug-Eluting Stents | 5 | 2021 | 67 | 0.310 |
Why?
|
| Myocardium | 1 | 2015 | 852 | 0.300 |
Why?
|
| Multidetector Computed Tomography | 3 | 2022 | 33 | 0.300 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2023 | 265 | 0.300 |
Why?
|
| Prescriptions | 4 | 2023 | 46 | 0.300 |
Why?
|
| Glucosides | 2 | 2020 | 55 | 0.300 |
Why?
|
| Prasugrel Hydrochloride | 3 | 2021 | 23 | 0.300 |
Why?
|
| Renin-Angiotensin System | 4 | 2024 | 104 | 0.300 |
Why?
|
| Apolipoproteins A | 3 | 2015 | 51 | 0.300 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2020 | 222 | 0.300 |
Why?
|
| United States Department of Defense | 2 | 2021 | 11 | 0.300 |
Why?
|
| Benzhydryl Compounds | 2 | 2020 | 79 | 0.290 |
Why?
|
| Colorectal Neoplasms | 2 | 2026 | 621 | 0.290 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2023 | 149 | 0.290 |
Why?
|
| Perioperative Care | 5 | 2014 | 217 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 2065 | 0.280 |
Why?
|
| Treatment Refusal | 2 | 2019 | 80 | 0.280 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2009 | 246 | 0.280 |
Why?
|
| RNA Interference | 2 | 2020 | 491 | 0.280 |
Why?
|
| Risk | 6 | 2019 | 726 | 0.280 |
Why?
|
| Linear Models | 7 | 2017 | 688 | 0.280 |
Why?
|
| Medically Uninsured | 5 | 2021 | 79 | 0.270 |
Why?
|
| Creatinine | 3 | 2023 | 398 | 0.270 |
Why?
|
| Patient Care Management | 2 | 2021 | 61 | 0.270 |
Why?
|
| Developing Countries | 3 | 2020 | 305 | 0.270 |
Why?
|
| Community Health Services | 2 | 2019 | 86 | 0.270 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 198 | 0.260 |
Why?
|
| Professional Practice Gaps | 2 | 2018 | 14 | 0.260 |
Why?
|
| Patient Compliance | 3 | 2020 | 463 | 0.260 |
Why?
|
| Oligonucleotides | 2 | 2020 | 94 | 0.260 |
Why?
|
| Ultrasonography, Doppler | 3 | 2014 | 187 | 0.260 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 387 | 0.260 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 293 | 0.260 |
Why?
|
| Dietary Fats | 2 | 2021 | 278 | 0.250 |
Why?
|
| Phenotype | 11 | 2024 | 4497 | 0.250 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2023 | 482 | 0.250 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2025 | 50 | 0.250 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2023 | 36 | 0.250 |
Why?
|
| Heart Transplantation | 2 | 2025 | 800 | 0.250 |
Why?
|
| Patient Readmission | 4 | 2023 | 442 | 0.240 |
Why?
|
| Pericarditis | 2 | 2020 | 45 | 0.240 |
Why?
|
| Apolipoproteins | 2 | 2019 | 69 | 0.240 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2024 | 362 | 0.240 |
Why?
|
| Influenza, Human | 3 | 2021 | 712 | 0.240 |
Why?
|
| Text Messaging | 2 | 2017 | 42 | 0.240 |
Why?
|
| Review Literature as Topic | 1 | 2026 | 55 | 0.230 |
Why?
|
| Pneumonia | 3 | 2021 | 341 | 0.230 |
Why?
|
| Vaccination | 2 | 2022 | 1060 | 0.230 |
Why?
|
| Length of Stay | 8 | 2023 | 1421 | 0.230 |
Why?
|
| Computed Tomography Angiography | 2 | 2024 | 216 | 0.230 |
Why?
|
| Machine Learning | 3 | 2025 | 387 | 0.230 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2022 | 361 | 0.230 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 492 | 0.220 |
Why?
|
| Self Report | 3 | 2024 | 554 | 0.220 |
Why?
|
| Health Resources | 2 | 2017 | 131 | 0.220 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2025 | 44 | 0.220 |
Why?
|
| Subtilisins | 3 | 2021 | 11 | 0.220 |
Why?
|
| Menopause | 1 | 2025 | 85 | 0.220 |
Why?
|
| Alopecia | 1 | 2025 | 41 | 0.220 |
Why?
|
| Cost Savings | 4 | 2018 | 79 | 0.220 |
Why?
|
| Heart-Assist Devices | 2 | 2024 | 1020 | 0.220 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2026 | 80 | 0.220 |
Why?
|
| Puberty | 1 | 2025 | 94 | 0.210 |
Why?
|
| Recurrence | 4 | 2026 | 1489 | 0.210 |
Why?
|
| Administration, Oral | 3 | 2021 | 711 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2024 | 3436 | 0.210 |
Why?
|
| Clinical Competence | 3 | 2019 | 1050 | 0.210 |
Why?
|
| Myocardial Revascularization | 3 | 2021 | 100 | 0.210 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2024 | 46 | 0.210 |
Why?
|
| Africa | 1 | 2024 | 135 | 0.210 |
Why?
|
| Genetic Variation | 4 | 2015 | 1559 | 0.210 |
Why?
|
| Internal Medicine | 2 | 2018 | 124 | 0.210 |
Why?
|
| Africa, Northern | 1 | 2023 | 10 | 0.210 |
Why?
|
| Vaccination Coverage | 2 | 2021 | 40 | 0.200 |
Why?
|
| Glucose | 3 | 2024 | 853 | 0.200 |
Why?
|
| Age Distribution | 5 | 2026 | 422 | 0.200 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2024 | 49 | 0.200 |
Why?
|
| Metabolic Equivalent | 2 | 2020 | 6 | 0.200 |
Why?
|
| Diabetes, Gestational | 1 | 2025 | 112 | 0.200 |
Why?
|
| Albuminuria | 3 | 2022 | 107 | 0.200 |
Why?
|
| Persian Gulf Syndrome | 1 | 2023 | 16 | 0.200 |
Why?
|
| Cognition | 2 | 2019 | 829 | 0.200 |
Why?
|
| Animals | 10 | 2025 | 33912 | 0.200 |
Why?
|
| Editorial Policies | 1 | 2024 | 49 | 0.200 |
Why?
|
| Leg | 2 | 2016 | 118 | 0.200 |
Why?
|
| Leisure Activities | 1 | 2023 | 11 | 0.200 |
Why?
|
| Nutrition Assessment | 1 | 2024 | 126 | 0.190 |
Why?
|
| Writing | 1 | 2024 | 59 | 0.190 |
Why?
|
| Pre-Eclampsia | 1 | 2025 | 226 | 0.190 |
Why?
|
| Angioedema | 1 | 2023 | 21 | 0.190 |
Why?
|
| Employment | 2 | 2020 | 74 | 0.190 |
Why?
|
| Live Birth | 1 | 2023 | 75 | 0.190 |
Why?
|
| Graves Disease | 1 | 2003 | 13 | 0.190 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 2085 | 0.190 |
Why?
|
| Pessimism | 1 | 2022 | 5 | 0.190 |
Why?
|
| Hearing Aids | 1 | 2023 | 30 | 0.190 |
Why?
|
| Yoga | 1 | 2023 | 13 | 0.190 |
Why?
|
| Social Class | 3 | 2022 | 214 | 0.190 |
Why?
|
| Hormone Replacement Therapy | 1 | 2025 | 187 | 0.190 |
Why?
|
| Heart Arrest | 3 | 2021 | 356 | 0.190 |
Why?
|
| Laboratories | 1 | 2023 | 81 | 0.190 |
Why?
|
| Internship and Residency | 2 | 2018 | 1223 | 0.190 |
Why?
|
| Emigrants and Immigrants | 2 | 2022 | 169 | 0.190 |
Why?
|
| Multimorbidity | 1 | 2022 | 23 | 0.190 |
Why?
|
| Celiac Disease | 1 | 2023 | 73 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 1618 | 0.180 |
Why?
|
| Quality of Life | 3 | 2022 | 2082 | 0.180 |
Why?
|
| Wine | 1 | 2022 | 15 | 0.180 |
Why?
|
| Patient Discharge | 3 | 2022 | 514 | 0.180 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 96 | 0.180 |
Why?
|
| Hematoma | 1 | 2022 | 85 | 0.180 |
Why?
|
| Diet | 2 | 2021 | 1121 | 0.180 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 341 | 0.180 |
Why?
|
| Hospitals, Veterans | 4 | 2020 | 336 | 0.180 |
Why?
|
| Motivation | 3 | 2019 | 328 | 0.180 |
Why?
|
| Myocarditis | 1 | 2023 | 122 | 0.180 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 2602 | 0.180 |
Why?
|
| Resistance Training | 1 | 2022 | 26 | 0.180 |
Why?
|
| Mortality, Premature | 1 | 2021 | 13 | 0.180 |
Why?
|
| Malnutrition | 1 | 2024 | 163 | 0.180 |
Why?
|
| Public Health | 1 | 2024 | 269 | 0.180 |
Why?
|
| Overweight | 2 | 2022 | 387 | 0.170 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 77 | 0.170 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2021 | 6 | 0.170 |
Why?
|
| Models, Economic | 2 | 2019 | 59 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 1071 | 0.170 |
Why?
|
| Health Services Misuse | 1 | 2021 | 23 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 204 | 0.170 |
Why?
|
| Dabigatran | 1 | 2021 | 26 | 0.170 |
Why?
|
| Pancreatitis | 1 | 2022 | 139 | 0.170 |
Why?
|
| Galectin 3 | 1 | 2021 | 32 | 0.170 |
Why?
|
| Protein Precursors | 3 | 2021 | 140 | 0.170 |
Why?
|
| Fish Products | 1 | 2021 | 1 | 0.170 |
Why?
|
| Epidemics | 1 | 2021 | 58 | 0.170 |
Why?
|
| Aging | 4 | 2024 | 1242 | 0.170 |
Why?
|
| Fishes | 1 | 2021 | 32 | 0.170 |
Why?
|
| Agaricales | 1 | 2020 | 7 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 3 | 2018 | 226 | 0.170 |
Why?
|
| Mental Recall | 1 | 2021 | 138 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2020 | 761 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 1 | 2021 | 169 | 0.160 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 19 | 0.160 |
Why?
|
| Reproducibility of Results | 9 | 2023 | 2904 | 0.160 |
Why?
|
| Atrial Appendage | 1 | 2021 | 77 | 0.160 |
Why?
|
| Risk-Taking | 1 | 2021 | 96 | 0.160 |
Why?
|
| Sleep | 1 | 2024 | 381 | 0.160 |
Why?
|
| Thiazoles | 1 | 2021 | 113 | 0.160 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2020 | 23 | 0.160 |
Why?
|
| Telecommunications | 1 | 2020 | 21 | 0.160 |
Why?
|
| Economic Recession | 1 | 2020 | 2 | 0.160 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2020 | 15 | 0.160 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 10 | 0.160 |
Why?
|
| Rural Population | 2 | 2021 | 276 | 0.160 |
Why?
|
| Bioprosthesis | 1 | 2021 | 110 | 0.160 |
Why?
|
| Walking | 1 | 2022 | 230 | 0.160 |
Why?
|
| Meditation | 1 | 2020 | 21 | 0.160 |
Why?
|
| Pets | 1 | 2020 | 19 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 70 | 0.160 |
Why?
|
| Prescription Fees | 1 | 2019 | 3 | 0.160 |
Why?
|
| Pyridones | 1 | 2021 | 140 | 0.160 |
Why?
|
| Disease Progression | 2 | 2024 | 2200 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2025 | 464 | 0.150 |
Why?
|
| Qualitative Research | 2 | 2021 | 730 | 0.150 |
Why?
|
| Fever | 1 | 2022 | 312 | 0.150 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 40 | 0.150 |
Why?
|
| Ownership | 1 | 2020 | 33 | 0.150 |
Why?
|
| Interleukin-8 | 1 | 2020 | 200 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 53 | 0.150 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 58 | 0.150 |
Why?
|
| Testosterone | 1 | 2025 | 531 | 0.150 |
Why?
|
| Hospitals | 4 | 2023 | 435 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2019 | 645 | 0.150 |
Why?
|
| Particulate Matter | 1 | 2020 | 93 | 0.150 |
Why?
|
| Suburban Population | 1 | 2019 | 7 | 0.150 |
Why?
|
| Child | 6 | 2026 | 26341 | 0.150 |
Why?
|
| Pyridines | 1 | 2021 | 255 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2023 | 283 | 0.150 |
Why?
|
| Ultrasonic Therapy | 1 | 2019 | 26 | 0.150 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 267 | 0.150 |
Why?
|
| Air Pollution | 1 | 2020 | 79 | 0.150 |
Why?
|
| Observational Studies as Topic | 2 | 2022 | 106 | 0.150 |
Why?
|
| Interleukin-10 | 1 | 2020 | 192 | 0.150 |
Why?
|
| Heart | 1 | 2024 | 650 | 0.150 |
Why?
|
| General Practitioners | 1 | 2019 | 18 | 0.150 |
Why?
|
| Pneumococcal Vaccines | 1 | 2021 | 174 | 0.150 |
Why?
|
| Precision Medicine | 2 | 2022 | 388 | 0.150 |
Why?
|
| Disease Management | 3 | 2020 | 558 | 0.150 |
Why?
|
| Resuscitation | 1 | 2021 | 258 | 0.150 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 1833 | 0.150 |
Why?
|
| Algorithms | 5 | 2025 | 1680 | 0.150 |
Why?
|
| Telomere | 1 | 2020 | 219 | 0.150 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 66 | 0.140 |
Why?
|
| Nepal | 1 | 2019 | 25 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 573 | 0.140 |
Why?
|
| Health Education | 1 | 2020 | 228 | 0.140 |
Why?
|
| Chronic Disease | 5 | 2024 | 1246 | 0.140 |
Why?
|
| Heterozygote | 1 | 2021 | 737 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 182 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2021 | 1483 | 0.140 |
Why?
|
| Pulmonary Embolism | 2 | 2019 | 182 | 0.140 |
Why?
|
| Patients | 1 | 2019 | 122 | 0.140 |
Why?
|
| Mass Screening | 2 | 2015 | 822 | 0.140 |
Why?
|
| Air Pollutants | 1 | 2020 | 124 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 369 | 0.140 |
Why?
|
| Sodium | 2 | 2024 | 280 | 0.140 |
Why?
|
| Cardiac Catheterization | 3 | 2021 | 630 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 104 | 0.140 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 1224 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 2021 | 281 | 0.140 |
Why?
|
| Area Under Curve | 3 | 2025 | 304 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2021 | 349 | 0.140 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2017 | 227 | 0.140 |
Why?
|
| Health Facilities | 1 | 2018 | 66 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 303 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 294 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 639 | 0.140 |
Why?
|
| Documentation | 1 | 2019 | 121 | 0.140 |
Why?
|
| Sick Sinus Syndrome | 1 | 2018 | 17 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2003 | 457 | 0.130 |
Why?
|
| Depression | 2 | 2025 | 1320 | 0.130 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2017 | 6 | 0.130 |
Why?
|
| Cognition Disorders | 2 | 2019 | 556 | 0.130 |
Why?
|
| Blood Pressure Determination | 2 | 2016 | 118 | 0.130 |
Why?
|
| Blood Component Removal | 1 | 2018 | 35 | 0.130 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 187 | 0.130 |
Why?
|
| Education | 1 | 2018 | 112 | 0.130 |
Why?
|
| Apolipoprotein A-I | 3 | 2013 | 80 | 0.130 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 58 | 0.130 |
Why?
|
| Thigh | 2 | 2022 | 50 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2022 | 824 | 0.130 |
Why?
|
| Gene Frequency | 3 | 2019 | 729 | 0.130 |
Why?
|
| Off-Label Use | 1 | 2017 | 29 | 0.130 |
Why?
|
| Arteriosclerosis | 1 | 2017 | 109 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2015 | 272 | 0.130 |
Why?
|
| Pregnancy | 4 | 2026 | 7512 | 0.130 |
Why?
|
| Anthropometry | 2 | 2014 | 187 | 0.130 |
Why?
|
| Lipoprotein Lipase | 2 | 2014 | 60 | 0.120 |
Why?
|
| Pharmacists | 1 | 2017 | 104 | 0.120 |
Why?
|
| Rosuvastatin Calcium | 1 | 2016 | 42 | 0.120 |
Why?
|
| Stents | 5 | 2016 | 799 | 0.120 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 151 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2020 | 3359 | 0.120 |
Why?
|
| Femoral Vein | 1 | 2016 | 42 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 229 | 0.120 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2016 | 29 | 0.120 |
Why?
|
| Religious Personnel | 1 | 2015 | 1 | 0.120 |
Why?
|
| Protestantism | 1 | 2015 | 4 | 0.120 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 59 | 0.120 |
Why?
|
| Postoperative Hemorrhage | 2 | 2020 | 83 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 56 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2021 | 715 | 0.110 |
Why?
|
| Occupational Health | 1 | 2015 | 43 | 0.110 |
Why?
|
| Renal Dialysis | 3 | 2020 | 951 | 0.110 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 193 | 0.110 |
Why?
|
| Intestinal Absorption | 1 | 2016 | 170 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 371 | 0.110 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 25 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 878 | 0.110 |
Why?
|
| Double-Blind Method | 6 | 2016 | 1626 | 0.110 |
Why?
|
| Prehypertension | 1 | 2015 | 9 | 0.110 |
Why?
|
| Reimbursement, Incentive | 1 | 2015 | 48 | 0.110 |
Why?
|
| Pericardiocentesis | 1 | 2015 | 17 | 0.110 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2015 | 12 | 0.110 |
Why?
|
| Research Personnel | 1 | 2016 | 139 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2016 | 230 | 0.110 |
Why?
|
| Postprandial Period | 1 | 2015 | 93 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 61 | 0.110 |
Why?
|
| Mississippi | 2 | 2024 | 35 | 0.110 |
Why?
|
| Health Services Research | 2 | 2016 | 180 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 1545 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 209 | 0.110 |
Why?
|
| Angina, Unstable | 1 | 2014 | 50 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 338 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 650 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 204 | 0.100 |
Why?
|
| Ultrasonography | 2 | 2015 | 943 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2015 | 73 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 232 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 726 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 563 | 0.100 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 13 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 819 | 0.100 |
Why?
|
| Reference Values | 3 | 2011 | 676 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2015 | 176 | 0.100 |
Why?
|
| ROC Curve | 3 | 2012 | 613 | 0.100 |
Why?
|
| Triage | 1 | 2014 | 144 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 905 | 0.100 |
Why?
|
| Brain Infarction | 1 | 2013 | 28 | 0.100 |
Why?
|
| Hyponatremia | 1 | 2014 | 73 | 0.100 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 808 | 0.100 |
Why?
|
| Tangier Disease | 1 | 2012 | 6 | 0.090 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2010 | 161 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2014 | 161 | 0.090 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 63 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2025 | 825 | 0.090 |
Why?
|
| Rare Diseases | 1 | 2015 | 210 | 0.090 |
Why?
|
| Geriatric Assessment | 2 | 2024 | 184 | 0.090 |
Why?
|
| Problem Solving | 1 | 2012 | 61 | 0.090 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 17 | 0.090 |
Why?
|
| Platelet Aggregation | 2 | 2011 | 100 | 0.090 |
Why?
|
| Health Promotion | 1 | 2015 | 422 | 0.090 |
Why?
|
| Mutation | 3 | 2024 | 6099 | 0.090 |
Why?
|
| General Surgery | 1 | 2014 | 224 | 0.090 |
Why?
|
| Vascular Grafting | 1 | 2012 | 51 | 0.090 |
Why?
|
| Florida | 2 | 2015 | 73 | 0.090 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 46 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 533 | 0.090 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 194 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1591 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2012 | 331 | 0.080 |
Why?
|
| Family Practice | 1 | 2011 | 84 | 0.080 |
Why?
|
| Muscles | 1 | 2011 | 197 | 0.080 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 802 | 0.080 |
Why?
|
| Necrosis | 1 | 2011 | 192 | 0.080 |
Why?
|
| Platelet Function Tests | 1 | 2011 | 37 | 0.080 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 161 | 0.080 |
Why?
|
| Stress, Psychological | 2 | 2023 | 536 | 0.080 |
Why?
|
| Forecasting | 2 | 2024 | 351 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 142 | 0.080 |
Why?
|
| Health Policy | 2 | 2023 | 234 | 0.080 |
Why?
|
| Asia, Western | 2 | 2021 | 5 | 0.080 |
Why?
|
| Nutritional Status | 2 | 2024 | 298 | 0.080 |
Why?
|
| Aftercare | 2 | 2022 | 157 | 0.080 |
Why?
|
| Particle Size | 2 | 2024 | 135 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2013 | 468 | 0.080 |
Why?
|
| HIV Infections | 1 | 2022 | 2049 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8635 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 1207 | 0.070 |
Why?
|
| Apolipoprotein A-V | 3 | 2015 | 21 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2021 | 263 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2012 | 749 | 0.070 |
Why?
|
| Endocrinology | 1 | 2011 | 124 | 0.070 |
Why?
|
| Muscle, Skeletal | 3 | 2022 | 981 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2011 | 185 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 787 | 0.070 |
Why?
|
| Pulse Wave Analysis | 2 | 2021 | 48 | 0.070 |
Why?
|
| Sarcoidosis | 1 | 2009 | 50 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 587 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 247 | 0.070 |
Why?
|
| Syndrome | 2 | 2012 | 1155 | 0.070 |
Why?
|
| Tachycardia, Ventricular | 2 | 2021 | 257 | 0.070 |
Why?
|
| Electric Countershock | 2 | 2020 | 74 | 0.070 |
Why?
|
| Perception | 2 | 2021 | 231 | 0.070 |
Why?
|
| Sepsis | 1 | 2012 | 493 | 0.070 |
Why?
|
| Peroxidase | 1 | 2008 | 63 | 0.070 |
Why?
|
| Incidental Findings | 1 | 2009 | 122 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 2 | 2022 | 205 | 0.070 |
Why?
|
| Contrast Media | 1 | 2011 | 474 | 0.070 |
Why?
|
| Ankle Brachial Index | 1 | 2007 | 40 | 0.070 |
Why?
|
| Cardiac Tamponade | 1 | 2008 | 35 | 0.070 |
Why?
|
| Phospholipases A2 | 1 | 2007 | 31 | 0.070 |
Why?
|
| Phospholipases A | 1 | 2007 | 31 | 0.070 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2008 | 61 | 0.060 |
Why?
|
| Genotype | 1 | 2013 | 2595 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2007 | 111 | 0.060 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2008 | 77 | 0.060 |
Why?
|
| Cor Triatriatum | 1 | 2007 | 11 | 0.060 |
Why?
|
| Acute Disease | 2 | 2022 | 1153 | 0.060 |
Why?
|
| Food Labeling | 1 | 2026 | 12 | 0.060 |
Why?
|
| Graft Survival | 1 | 2008 | 465 | 0.060 |
Why?
|
| Pennsylvania | 1 | 2026 | 60 | 0.060 |
Why?
|
| Long QT Syndrome | 1 | 2007 | 86 | 0.060 |
Why?
|
| Menopause, Premature | 1 | 2025 | 6 | 0.060 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2005 | 42 | 0.060 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 44 | 0.060 |
Why?
|
| Weight Loss | 2 | 2019 | 538 | 0.060 |
Why?
|
| Parity | 1 | 2025 | 77 | 0.060 |
Why?
|
| Allografts | 1 | 2025 | 220 | 0.050 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2024 | 17 | 0.050 |
Why?
|
| Massachusetts | 1 | 2024 | 122 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 776 | 0.050 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 45 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 223 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 530 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2026 | 245 | 0.050 |
Why?
|
| Government Programs | 1 | 2023 | 11 | 0.050 |
Why?
|
| Oral Health | 1 | 2023 | 28 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2023 | 35 | 0.050 |
Why?
|
| Gulf War | 1 | 2023 | 9 | 0.050 |
Why?
|
| Albumins | 1 | 2023 | 87 | 0.050 |
Why?
|
| World Health Organization | 1 | 2023 | 118 | 0.050 |
Why?
|
| Curriculum | 2 | 2019 | 798 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 2023 | 75 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 89 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2018 | 351 | 0.050 |
Why?
|
| Atherectomy | 1 | 2022 | 11 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 144 | 0.050 |
Why?
|
| Thiazides | 1 | 2022 | 5 | 0.050 |
Why?
|
| Chlorthalidone | 1 | 2022 | 25 | 0.050 |
Why?
|
| Beer | 1 | 2022 | 3 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2025 | 224 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 28 | 0.050 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 35 | 0.050 |
Why?
|
| Alcoholic Beverages | 1 | 2022 | 16 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2023 | 211 | 0.050 |
Why?
|
| Spain | 1 | 2022 | 56 | 0.050 |
Why?
|
| Microcirculation | 1 | 2022 | 104 | 0.050 |
Why?
|
| Azetidines | 2 | 2013 | 60 | 0.050 |
Why?
|
| Nigeria | 1 | 2022 | 71 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 79 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2022 | 107 | 0.040 |
Why?
|
| Asia, Southeastern | 1 | 2021 | 23 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2022 | 77 | 0.040 |
Why?
|
| New Mexico | 1 | 2021 | 7 | 0.040 |
Why?
|
| Attitude | 1 | 2022 | 111 | 0.040 |
Why?
|
| Arizona | 1 | 2021 | 25 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 2021 | 51 | 0.040 |
Why?
|
| Smokers | 1 | 2021 | 48 | 0.040 |
Why?
|
| Bibliometrics | 1 | 2021 | 37 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 263 | 0.040 |
Why?
|
| California | 1 | 2021 | 127 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2021 | 106 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 190 | 0.040 |
Why?
|
| Data Mining | 1 | 2021 | 68 | 0.040 |
Why?
|
| Fertility | 1 | 2023 | 260 | 0.040 |
Why?
|
| Cooking | 1 | 2021 | 39 | 0.040 |
Why?
|
| Ethanol | 1 | 2022 | 170 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 34 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 30 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2024 | 245 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 321 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 16 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2020 | 30 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 119 | 0.040 |
Why?
|
| Haplotypes | 2 | 2012 | 519 | 0.040 |
Why?
|
| Marital Status | 1 | 2020 | 32 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 137 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 35 | 0.040 |
Why?
|
| Cats | 1 | 2020 | 117 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 109 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 97 | 0.040 |
Why?
|
| Indians, North American | 1 | 2020 | 71 | 0.040 |
Why?
|
| Endocarditis | 1 | 2020 | 102 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 170 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 386 | 0.040 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2025 | 402 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 156 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2019 | 78 | 0.040 |
Why?
|
| Food Supply | 1 | 2020 | 94 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 190 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Certification | 1 | 2019 | 71 | 0.040 |
Why?
|
| Cinchona Alkaloids | 1 | 1998 | 2 | 0.040 |
Why?
|
| Dogs | 1 | 2020 | 613 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 409 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2019 | 76 | 0.040 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 122 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 195 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 286 | 0.040 |
Why?
|
| Antimalarials | 1 | 1998 | 40 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2020 | 348 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2020 | 294 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2019 | 365 | 0.030 |
Why?
|
| Reoperation | 1 | 2021 | 818 | 0.030 |
Why?
|
| Insurance | 1 | 2017 | 8 | 0.030 |
Why?
|
| Acacia | 1 | 1997 | 2 | 0.030 |
Why?
|
| Fear | 1 | 2019 | 190 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 122 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 37 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 101 | 0.030 |
Why?
|
| Drug Approval | 1 | 2017 | 48 | 0.030 |
Why?
|
| Hospital Charges | 1 | 2017 | 70 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 107 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 144 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2018 | 164 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2019 | 114 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2020 | 298 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2024 | 15110 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2008 | 113 | 0.030 |
Why?
|
| Drugs, Generic | 1 | 2017 | 16 | 0.030 |
Why?
|
| Medicare Part D | 1 | 2016 | 12 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2016 | 27 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2020 | 385 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 25 | 0.030 |
Why?
|
| Ticlopidine | 1 | 2016 | 28 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 173 | 0.030 |
Why?
|
| Independent Living | 1 | 2016 | 64 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2017 | 188 | 0.030 |
Why?
|
| Blood Volume | 1 | 2016 | 73 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 195 | 0.030 |
Why?
|
| Adenosine Diphosphate | 2 | 2011 | 48 | 0.030 |
Why?
|
| Arachidonic Acid | 2 | 2011 | 52 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1997 | 130 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1216 | 0.030 |
Why?
|
| Cystatin C | 1 | 2016 | 70 | 0.030 |
Why?
|
| Sexism | 1 | 2016 | 44 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2022 | 1106 | 0.030 |
Why?
|
| Education, Medical | 1 | 2019 | 293 | 0.030 |
Why?
|
| Cholesterol, VLDL | 1 | 2015 | 17 | 0.030 |
Why?
|
| Ultracentrifugation | 1 | 2015 | 20 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 960 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 159 | 0.030 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2017 | 178 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 443 | 0.030 |
Why?
|
| Utilization Review | 1 | 2015 | 39 | 0.030 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 75 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 27 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 807 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 154 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 327 | 0.030 |
Why?
|
| Apolipoprotein B-100 | 1 | 2014 | 36 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 197 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 129 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1796 | 0.020 |
Why?
|
| Exome | 1 | 2018 | 1061 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2017 | 324 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 89 | 0.020 |
Why?
|
| Patient Admission | 1 | 2014 | 185 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2013 | 134 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 201 | 0.020 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 21 | 0.020 |
Why?
|
| Netherlands | 1 | 2012 | 55 | 0.020 |
Why?
|
| Corneal Stroma | 1 | 2012 | 79 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 80 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 441 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 19 | 0.020 |
Why?
|
| Metals | 1 | 2012 | 70 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2012 | 63 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 40 | 0.020 |
Why?
|
| Automation | 1 | 2011 | 65 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2011 | 19 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 775 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2012 | 243 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2011 | 242 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 384 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 1677 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 483 | 0.020 |
Why?
|
| Retreatment | 1 | 2008 | 85 | 0.020 |
Why?
|
| Pravastatin | 1 | 2008 | 22 | 0.020 |
Why?
|
| Syncope | 1 | 2009 | 52 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1827 | 0.020 |
Why?
|
| Aortography | 1 | 2009 | 155 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2008 | 79 | 0.020 |
Why?
|
| Microspheres | 1 | 2008 | 66 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 690 | 0.020 |
Why?
|
| Fluorocarbons | 1 | 2008 | 66 | 0.020 |
Why?
|
| Pyrroles | 1 | 2008 | 188 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1882 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 164 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1998 | 4686 | 0.010 |
Why?
|
| Biopsy | 1 | 2009 | 1239 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 225 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 3175 | 0.010 |
Why?
|
| Calcimycin | 1 | 1998 | 19 | 0.010 |
Why?
|
| Platelet Activating Factor | 1 | 1998 | 22 | 0.010 |
Why?
|
| Epinephrine | 1 | 1998 | 150 | 0.010 |
Why?
|
| Ion Transport | 1 | 1997 | 48 | 0.010 |
Why?
|
| Collagen | 1 | 1998 | 273 | 0.010 |
Why?
|